Amplexd Therapeutics initiates phase 2 trial of EGCg-based HPV therapy
May 19, 2026 | 11:56
Amplexd Therapeutics started a phase 2 clinical trial of an investigational EGCg-based therapy for HPV, offering a potential new treatment option for patients with persistent infections.
Mobile Version